Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

InMed Pharmaceuticals (INM) Accumulated Depreciation & Amortization: 2021-2025

Historic Accumulated Depreciation & Amortization for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2025 value amounting to $1.3 million.

  • InMed Pharmaceuticals' Accumulated Depreciation & Amortization fell 1.25% to $1.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.7 million, marking a year-over-year decrease of 0.62%. This contributed to the annual value of $1.3 million for FY2025, which is 1.25% down from last year.
  • As of Q2 2025, InMed Pharmaceuticals' Accumulated Depreciation & Amortization stood at $1.3 million, which was up 10.48% from $1.2 million recorded in Q1 2025.
  • In the past 5 years, InMed Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $1.4 million in Q2 2024 and a low of $244,261 during Q3 2021.
  • In the last 3 years, InMed Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $1.1 million in 2023 and averaged $1.1 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 153.15% in 2022, then declined by 1.86% in 2025.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Accumulated Depreciation & Amortization stood at $320,520 in 2021, then soared by 123.64% to $716,800 in 2022, then spiked by 56.84% to $1.1 million in 2023, then grew by 1.43% to $1.1 million in 2024, then decreased by 1.25% to $1.3 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $1.3 million for Q2 2025, versus $1.2 million for Q1 2025 and $1.1 million for Q4 2024.